Skip to main content

Table 2 Alternative antifungal agents given after treatment failure with Voriconazole or LAmB

From: Pharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey

Reason for treatment failure

Alternative given

Voriconazole arm

LAmB arm

Infusion-related reactionsa

Caspofunginb

Voriconazolec

Nephrotoxicity

Caspofunginb

Caspofunginb

Hepatotoxicity

LAmBd

Caspofunginb

Suspected fungal infection

LAmBe

Voriconazolec

Persistent fever

LAmBe

Voriconazolec

Breakthrough fungal infection

Aspergillus spp.

LAmBd

Voriconazolec

Candida spp.

Caspofunginb

Caspofunginb

Zygomycetes spp.

LAmBe

N/A

DematiaceousMoulds

N/A

LAmB plus posaconazolef

Moulds not identified

N/A

LAmBe

Non-responding baseline fungal infection

Aspergillus spp.

LAmBd

Voriconazolec

Candida spp.

Caspofunginb

Caspofunginb

Zygomycetes spp.

LAmB plus posaconazolef

N/A

Trichoderma fungemia

N/A

Voriconazolec

Fusarium spp.

N/A

LAmB plus posaconazolef

Moulds not identified

N/A

LAmB plus posaconazolef

  1. aA switch to alternative therapy due to infusion-related reactions included commencement of pre-dose diphenhydramine; bCaspofungin dose 70 mg on day one, 50 mg thereafter; cVoriconazole dose 6 mg/kg i.v. twice daily on day one, 4 mg/kg i.v. twice daily or 400 mg p.o. twice daily thereafter (22% in base case received oral voriconazole); dLAmB dose 3 mg/kg/day; eLAmB 5 mg/kg/day; fLAmB dose 5 mg/kg/day, posaconazole 200 mg four times per day.